DrugPatentWatch Database Preview
Neopharma Company Profile
» See Plans and Pricing
What is the competitive landscape for NEOPHARMA, and what generic alternatives to NEOPHARMA drugs are available?
NEOPHARMA has twenty approved drugs.
There are five US patents protecting NEOPHARMA drugs.
There are ninety-three patent family members on NEOPHARMA drugs in forty-eight countries and twenty-six supplementary protection certificates in nine countries.
Summary for Neopharma
| International Patents: | 93 |
| US Patents: | 5 |
| Tradenames: | 16 |
| Ingredients: | 8 |
| NDAs: | 20 |
Drugs and US Patents for Neopharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neopharma | AMOXIL | amoxicillin | TABLET;ORAL | 050754-001 | Jul 10, 1998 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Neopharma | AMOXIL | amoxicillin | FOR SUSPENSION;ORAL | 050760-001 | Apr 15, 1999 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| Neopharma | AUGMENTIN '400' | amoxicillin; clavulanate potassium | FOR SUSPENSION;ORAL | 050725-002 | May 31, 1996 | DISCN | Yes | No | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Neopharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Neopharma | AUGMENTIN XR | amoxicillin; clavulanate potassium | TABLET, EXTENDED RELEASE;ORAL | 050785-001 | Sep 25, 2002 | 6,746,692 | Start Trial |
| Neopharma | AUGMENTIN XR | amoxicillin; clavulanate potassium | TABLET, EXTENDED RELEASE;ORAL | 050785-001 | Sep 25, 2002 | 7,250,176 | Start Trial |
| Neopharma | AUGMENTIN XR | amoxicillin; clavulanate potassium | TABLET, EXTENDED RELEASE;ORAL | 050785-001 | Sep 25, 2002 | 6,783,773 | Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for NEOPHARMA drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 1000 mg/62.5 mg | ➤ Subscribe | 2009-01-21 |
International Patents for Neopharma Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Norway | 20014960 | Start Trial |
| South Korea | 20020015311 | Start Trial |
| Ukraine | 71609 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Neopharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0296749 | 97C0023 | France | Start Trial | PRODUCT NAME: ANASTROZOLE, EVENTUELLEMENT SOUS LA FORME D UN SEL D ADDITION ACCEPTABLE EN MEDECINE PHARMACEUTIQUE; NAT REG. NO/DATE: NL 21126 19961227; FIRST REG.: 12619/0106 19950811 |
| 0454511 | C990006 | Netherlands | Start Trial | PRODUCT NAME: IRBESARTAN, DESGEWENST IN DE VORM VAN EEN ZOUT EN/OF EEN HYDRAAT, EN HYDROCHLOORTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 - EU/1/98/086/006 19981015 |
| 1746976 | 300885 | Netherlands | Start Trial | PRODUCT NAME: ONIVYDE - IRINOTECAN; REGISTRATION NO/DATE: EU/1/16/1130 20161018 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
